Abstract Aim To evaluate the Pharmaceutical Care Network Europe (PCNE) classification system as a tool for documenting the impact of a hospital clinical pharmacology service. Setting Two medical wards comprising totally 85 beds in a university hospital. Main outcome measure Number of events classified with the PCNE-system, their acceptance by the medical staff and cost implications. Methods Clinical pharmacy review of pharmacotherapy on ward rounds and from case notes were documented, and identified drug-related problems (DRPs) were classified using the PCNE system version 5.00. Results During 70 observation days 216 interventions were registered of which 213 (98.6%) could be classified: 128 (60.1%) were detected by reviewing the case notes, 33 (15.5%) on ward rounds, 32 (15.0%) by direct reporting to the clinical pharmacist (CP), and 20 (9.4%) on non-formulary prescriptions. Of 148 suggested interventions by the CP 123 (83.0%) were approved by the responsible physician, 12 ADR reports (8.1%) were submitted to the local pharmacovigilance centre and 31 (20.9%) specific information given without further need for action. An evaluation of the DRPs showed that direct drug costs of €2,058 within the study period or €10,731 per year could be avoided.
Introduction
Drug-related problems are a major safety issue for hospitalized patients. A review of the literature from 1990 to 2005 found that on average 8% of hospitalised patients experience an adverse drug event (ADE), and 5-10% of all drug prescriptions or drug applications are erroneous [1] . In general internal medicine 14.6% of hospitalized patients and approximately 12% to 17% of patients after discharge experience ADEs [2, 3] . Interventions by clinical pharmacists have been shown to be effective in reducing DRPs with positive outcomes on the number of ADEs, medication appropriateness and resource use. A systematic literature review of controlled studies evaluating the effects of interventions by clinical pharmacists on hospitalized adults found that ADEs, adverse drug reactions (ADR) and MEs were reduced in 7 of 12 trials that included these outcomes [4] . Medication adherence, knowledge, and appropriateness of drug use improved in 7 of 11 studies and the length of hospital stay was shortened in 9 of 17 trials.
From an economic point of view clinical pharmacy services are also favourable. A summary of literature from 1996 to 2000 found 16 studies reporting a cost-benefit ratio ranging from 1.7:1 to 17:1 with a median of 4.68:1 [5] .
In many of these studies, however, definitions of detected or prevented problems such as ADRs, ADEs, medication errors or prescribing errors are not consistent. This may cause difficulties in documentation and classification of pharmaceutical interventions and may impair the comparability of the studies. A comprehensive overview of used definitions has been published recently [6] .
Due to the inconsistency of definition we have used the more general term of DRPs in this publication. A drugrelated problem (DRP) can be defined as an event or circumstance involving drug therapy that actually or potentially interferes with desired health outcomes [7] . It represents ineffective and unsafe drug use, which may cause or constitute risk factors for MEs, ADEs, ADRs [8] .
After having introduced a clinical pharmacy service on two wards we documented the effect of a clinical pharmacist's interventions on DRPs. The main objective was to evaluate the practicality of use of the classification system under daily conditions and to explore its usefulness to derive performance indicators of the clinical pharmacy service.
Methods

Classification system
Several classification systems have been proposed in the literature, with only some of them being validated [9] [10] [11] . We chose the PCNE classification system for drug-related problems (version 5.00) [7] , since it contains most of the required aspects described in a late review of classification systems [12] . To our knowledge the system has been used in primary care but not in hospital settings. To support continuity of care one single system for the documentation of clinical pharmacy activities is desirable. The PCNE system attributes four items to each observation-(1) coding for the problem itself, (2) the actual or suspected cause of the problem, (3) the intervention required to resolve the DRP, and (4) its outcome. An example to illustrate this code is given in Fig. 1 .
Study design and setting
We conducted a prospective, observational study of clinical pharmacy interventions in a tertiary 700-bed university hospital setting. The two observed wards (42 and 43 beds) included patients in general internal medicine, gastroenterology, oncology, nephrology and haematology.
During the period between May to December 2005 (32 weeks) one senior clinical pharmacist (ML) conducted 70 observation days taking part in clinical ward rounds and reviewing daily all the non-formulary prescriptions and the case notes of one of five nursing subunits of the ward (representing 10-15 patients). All clinical pharmaceutical interventions were classified as DRPs according to the PCNE System V5.00 and then entered into an Excel spread sheet (Microsoft Corp., Redmond, Oregon) including the drugs involved.
Acceptance of pharmacists' interventions
In the PCNE classification the items 11.3-11.5 were all considered suitable for a modification in therapy. Interventions at prescriber level proposing an approved change in drug therapy, were classified at drug level in order to get more detailed information. The acceptance rate was calculated as the sum of interventions with PCNE codes 11.3 and 13.x divided by the sum of all interventions proposing modifications (PCNE codes 11.3, 11.4, 11.5, and 13.x).
Cost avoidance
The cost avoidance of interventions directly linked to a reduction in medication usage was calculated. These interventions were: switching from i. As an assumption, we counted reduction of dosage as half price. Drug costs were calculated on the basis of defined daily doses and official prices given in the Swiss Drug Formulary [13] . In order to get a yearly estimate, all the directly cost-linked interventions during the 70 observation days were added up to a year of 365 working days.
Results
Classification of drug-related problems
In the observation period, 1, 444 patients were discharged from the two wards representing 17,476 patient days. There were 0.15 interventions per patient counting up to 1.22 interventions per 100 patient days.
A total of 213 pharmaceutical interventions were recorded, whereof 33 (15.5%) were initiated on ward rounds, 128 (60.1%) on case note review, 32 (15.0%) as a consequence of specific requests and 20 (9.4%) interventions by non-formulary drug orders. To each intervention a cause and a problem code could be attributed except six cases (2.8%) without a suitable problem category. The nonclassified problems are listed in Table 1 .
Problems
The major DRPs identified were related to incorrect drug choice (PCNE-Code P2) in 38% (n = 81); 24% (n = 52) were drug dosage problems (P3), followed by drug-drug or drug-food interactions (P5) in 17% (n = 37). ADRs (P1) accounted for 10% (n = 22) of the problems. The detailed analysis of the 207 DRPs are shown in Table 2 : potential drug interactions (16.4%, n = 34; P5.1) are most frequent, followed by overdose (14.5%, n = 30; P3.2) and inappropriate choice of drug form (12.6%, n = 26, P2.2), 20 (9.7%) problems regarding too low a dose (P3.1), 15 (7.2%) observations with no clear indication for drug use (P2.5) and 14 (6.8%) non-allergic ADRs (P1.1).
Causes
The overview of the causes (n = 213) shows a majority (68%, n = 145) that was related to the selection of the drug and/or dosage schedule (C1). The second most common cause with 15% (n = 33) involved the drug use process (C2), i.e., administration and timing of drugs. Patient factors (C4) seemed to play a minor role (1%, n = 2). Aspects concerning information about the treatment (C3), logistics (C5), e.g., availability of drugs, and other causes (C6) were noted each in 11 cases (5%).
The detailed analysis of the causes (Table 3) shows that pharmacokinetics due to organ dysfunction and interactions (C1.4) played a major role (19%) followed by inappropriate timing of administration and dosing intervals (C2.1; 11%, n = 24) and inappropriate drug selection (C1.1; 10%, n = 22).
Inverventions
All of the causes led to an intervention (n = 213). Most of them took place at the drug level (13; 54%, n = 116), followed by interventions at the prescriber level e.g. explaining a drug-drug interaction (11; 32%, n = 69). The rest of interventions were at the patient/carer level (12) or ''other activity'' (14) , each resulting in 7% (n = 14) of interventions (Table 4) . 
Acceptance indicator
In the PCNE classification the items 11.3 to 11.5 and all the interventions at drug level (13.x) can be considered as propositions for a modification in therapy (changes in drug prescription or other non-pharmacological measures such as the monitoring of drug levels or other laboratory parameters) subjected to physician's approval. In our sample 148 interventions of 213 concerned therapy modifications (69%). 83% were adopted by physicians (PCNE Codes 11.3/13.x, 6% were rejected (11.4), and in 16 cases (11%) the outcome remained unknown (11.5) (Fig. 2) . The remaining 65 interventions are not subject to physician approval. Almost half of these (47.7%, n = 31) involved giving more information to the prescriber, typically about potential drug-drug interactions requiring closer clinical patient monitoring. Another twelve interventions were ADRs reported to the pharmacovigilance centre.
Cost avoidance A total of 51 interventions (24%) were considered to be directly related to a cost saving without affecting quality of care (Table 5) .
Of these 51 cost-relevant interventions 22 (43.1%) accounted for stopping of medication, which was no longer required, 16 (31.4%) for switching from i.v. to p.o. medications and 13 (25.5%) for dosage adjustments.
The interventions stopping unnecessary drugs showed a mean saving of €10.11 resulting in €1,158 for the period of one year (365 working days). Interventions which switched the course of one year, the dose adjustment savings equal €1,788. Together, the cost-relevant interventions equal €10,731 for one year as mere cost avoidance not counting the effect on length of stay, ADE rate and possible litigation costs.
Discussion
Our study shows that of 213 interventions by the clinical pharmacist (CP) almost all (97.8%) could be documented and rated with the PCNE 5.00 system. By far the most DRPs were found in the realm of drug prescription. The classification of each DRP on four different levels (problem-cause-intervention-outcome) gives enough details allowing qualitative and economic analyses. As the PCNE system has been created for the documentation of DRPs in the public pharmacy setting, certain items are lacking for in-patients. Typical DRPs in the hospital setting like incompatibilities, application errors or faulty transcriptions cannot be coded in a satisfactory way; this should be taken into consideration when developing further versions of PCNE. The primary domain of the problems' section ''drug use problem'' is too restrictive and should be adapted for the in-hospital setting. Allenet et al. suggest such a documentation system. In their proposed intervention section it contains items often used like ''administration mode optimisation'' or ''change of administration route'', and in the problems section ''improper administration'' [10] . A major draw-back of their system is that neither a description of the cause nor options for the documentation of interventions at the patient level are provided. Combining the PCNE system with these elements would create a welladapted tool. Future work should additionally address the assessment of DRP severity and the clinical impact of the pharmacist's intervention as proposed in literature [14] [15] [16] .
Time is a key aspect for the acceptance of a documentation system. Practicability of the PCNE system in daily routine proved to be easy to use and barely time-consuming. The daily documentation classifying the DRP and entering the PCNE codes and the drugs into the database (Excel spreadsheet) took only a few minutes. Ganso using the PI-Doc system on a Microsoft Access database measured on average 1.9 min for the classification and 6.5 min for the electronic documentation/intervention [17] .
The documentation of DRPs with the PCNE system in everyday practice seems to provide realistic and comparable data about the impact of clinical pharmacy services on drug treatment. The acceptance of the pharmacist's interventions was 83%, a figure well in accordance with [18] . Some studies, however, may show acceptance rates of up to 99%, but the provision of drug information was also counted as an intervention, whereas in our calculation this item (PCNE 11.1: Prescriber informed only) was not included [19] . Clinical pharmacy service can reduce drug costs. Our study of a single CP's activity showed a cost avoidance of over 10,000 €/year. Twenty-five percent of interventions had direct influence on drug costs, a similar rate to the study of McMullin with 26% [20] . A recent study from Denmark assessed the cost effects of a clinical pharmacist in a controlled prospective study [21] . Cost reductions resulted in 43% of the interventions with total savings of direct drug costs of 3442 € within one year. The difference to our findings showing cost savings up to more than 10,000 €/year can be explained by methodological differences. Our results base on assumptions for calculation. Minor changes in the assumptions would lead to different results. Second, we extrapolate from our study period of 70 observation days in a period of 8 months to a whole year of 365 working days. In such a design random effects may occur (one single case with extraordinary high costs or cost savings) which are then extrapolated to one year.
But in spite of these restrictions, our findings do not seem unrealistic in comparison to other studies. Ganso found cost reductions ranging from 17 to 27 €/intervention on average in four different wards (3 surgery wards, 1 endocrinology ward) [17] whereas we calculated 34 €/intervention. In particular the cost savings of switching from i.v. to p.o. application is well within the range of former results. Our study confirms Ruettimann's cost savings of 93 € per switch of antibiotics [22] . Our estimations still are conservative taken into account we assumed work during daytime only.
Our study has several limitations. A major limitation is the possible bias in the detection and classification of DRPs since all the pharmaceutical interventions derive from a single site, a single medical floor and only one person identified, resolved and classified the DRPs. Using a crossover design with two pharmacists and kappa statistics would substantially reduce this bias. Local staffing restrictions unfortunately did not allow us to follow such a design. Furthermore, results from wards of other medical specialties should be compared to the medical wards in our study. Third, we show cost avoidance by the CP's interventions. The use of billing data, outcome measures and adjustment for age, gender and casemix, would enable real costs to be computed.
Conclusion
In conclusion, we consider the PCNE system with the four levels of classification a very useful and easy-to-use tool for the documentation of clinical pharmacy services not only for research purposes but also in daily hospital practice. Data generated by such a documentation system are increasingly important to provide information on the impact of the clinical pharmaceutical services supplied and identification of staff needs [23] .
